Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen announced that the FDA granted Breakthrough Therapy designation for its investigational KRASG12C inhibitor, sotorasib, aimed at treating patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. This designation underscores the unmet clinical need in a patient population lacking targeted therapies. Sotorasib is being tested in the CodeBreaK clinical program across 13 tumor types, with positive Phase 2 results indicating durable anticancer activity. Amgen plans to submit a new drug application by year-end 2020.
Amgen (NASDAQ:AMGN) has partnered with Karamo Brown to launch the Know Migraine Mission, aimed at increasing awareness and understanding of migraine. Karamo, who has suffered from migraines since high school, will share his experiences and encourage open conversations about the condition. Aimovig®, co-marketed with Novartis, is the first FDA-approved treatment for migraine prevention. The initiative focuses on combating stigma and promoting the significance of discussing migraine challenges, highlighting Aimovig's proven efficacy in reducing monthly migraine days.
Amgen announced its first presentation of clinical data for AMG 701, a half-life extended bispecific T cell engager, at the ASH Annual Meeting. Targeting BCMA, this immuno-oncology therapy was evaluated in 85 heavily pre-treated patients with relapsed/refractory multiple myeloma. The study revealed a 36% response rate, with some patients experiencing responses lasting up to 26 months. Adverse events included anemia (42%) and cytokine release syndrome (65%). This data emphasizes Amgen's commitment to innovative cancer treatments and the potential of the BiTE platform in addressing unmet medical needs.
Amgen and McKesson have established a multi-year strategic partnership aimed at enhancing cancer care in community oncology settings. With 1 in 5 cancer patients receiving an Amgen treatment and McKesson reaching 20% of U.S. cancer patients, this collaboration intends to optimize access to innovative therapies. The partnership will focus on improving molecular testing, treatment patterns, and utilizing real-world data to enhance patient care. The initiative emphasizes reducing disparities in cancer treatment across diverse demographics.
Amgen (NASDAQ:AMGN) will host a webcast on December 8, 2020, at 4:00 p.m. ET, following the 62nd American Society of Hematology Annual Meeting. Led by David M. Reese, the call will focus on the company's oncology and hematology programs, particularly the innovative BiTE® platform. Key topics will include the first clinical data for AMG 701 and results from a Phase 3 pediatric study of BLINCYTO® (blinatumomab). The webcast will be available on Amgen's website and archived for 90 days.
Amgen (NASDAQ:AMGN) will present key data at the 62nd American Society of Hematology Annual Meeting from Dec. 5-8, 2020. Highlights include findings from the Phase 1 study of AMG 701, targeting BCMA for relapsed/refractory multiple myeloma. The data also features analyses from the BLINCYTO Phase 3 study for children with high-risk B-ALL. Amgen emphasizes its robust bispecific T cell engager (BiTE®) portfolio, showcasing first-in-human data. Additional presentations will cover updates from the KYPROLIS Phase 3 CANDOR study.
Amgen (NASDAQ:AMGN) is set to present at the Evercore ISI Virtual HealthCONx Conference on Dec. 1, 2020, at 1:50 p.m. ET. Key executives, including David M. Reese and Peter H. Griffith, will lead the presentation. Interested parties can access the live audio on Amgen's website under the Events Calendar, with a replay available for 90 days. Amgen is focused on innovative therapeutics and addressing unmet medical needs, aiming to improve health outcomes globally. More details can be found at www.amgen.com.
Amgen (NASDAQ:AMGN) has announced the termination of its collaboration with Cytokinetics and plans to transfer development and commercialization rights for cardiac treatments omecamtiv mecarbil and AMG 594. The recent GALACTIC-HF trial results showed a significant reduction in the risk of cardiovascular death or heart failure events but failed to meet secondary endpoints. Despite disappointing results, Amgen remains committed to cardiovascular innovation, including ongoing development of their Lp(a) inhibitor, olpasiran (AMG 890), currently in Phase 2 trials.
Amgen (NASDAQ:AMGN) will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:00 p.m. ET. The presentation will be led by Peter H. Griffith, executive vice president and CFO of Amgen. Interested parties can access the live audio through the Events Calendar on Amgen's website, with a replay available for at least 90 days post-event. As a leader in biotechnology, Amgen is dedicated to discovering innovative therapies for serious illnesses, leveraging advanced human genetics to enhance health outcomes.
Amgen will present at the Cowen 4th Annual Virtual IO Summit on November 13, 2020, at 3:30 p.m. ET. David M. Reese, M.D., executive vice president of Research and Development, will lead the presentation. Live audio will stream from Amgen's website, with a replay available for 90 days post-event. Amgen, a leader in biotechnology since 1980, focuses on innovative human therapeutics to address serious illnesses and unmet medical needs. The company is dedicated to improving health outcomes globally.